Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2007

Cepheid to Develop Cervical Cancer Test with HPV Technology from Quantovir

  • Cepheid will exclusively license Quantovir’s HPV patent portfolio to develop a diagnostic for cervical cancer. Quantovir has reportedly demonstrated that a molecular test measuring the viral load of HPV DNA present in cervical specimens can be used to predict a woman’s risk of developing cervical cancer.

    Cepheid plans to develop a quantitative measurement of high-risk HPV types for the GeneXpert® System. The test is expected to provide accurate PCR results in minutes rather than days in a variety of clinical settings, according to John L. Bishop, CEO of Cepheid.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »